Review synthesizes recent studies on CAR-T cell therapy's safety and efficacy in pediatric ALL, suggesting key areas for improvement.
Key Points
CAR-T cell therapy achieves complete remission rates up to 100% in pediatric ALL cases, indicating strong treatment efficacy.
Safety profiles are manageable with common adverse effects like cytokine release syndrome and neurotoxicity, warranting careful monitoring.
Literature review covering 12 studies from 2014 to 2024 highlights the need for biomarkers for response prediction in pediatric patients.
Potential challenges remain in adverse effect management, particularly concerning cytokine release syndrome and neurotoxicity, signaling need for optimization.